Presentations

This presentation aims to analyse the occurrence of stavudine (d4T) related toxicity in a large cohort of patients on highly active antiretroviral therapy (HAART).

This is a presentation on results obtained from the implementation of the project, "A comprehensive intervention based on peer education for injecting drug users" in Lang Son. The objective of this project is to restrain HIV/AIDS epidemic within IDUs and from this group in to community in Lang Son.

Background:

• In February 2004, MSF-B started pediatric HIV/AIDS care in Takeo in collaboration with the hospital pediatric team
• Located and extended nearby the pediatric ward in the compound of Daunkeo RH, Takeo provincial town
• Staff: Hospital pediatric team + MSF-B staff

HIV/AIDS situation in Cambodia

• First HIV detected in 1991
• First AIDS case diagnosed in 1993
• Main route of HIV transmission: heterosexual
• 1998: 179,000 people living with HIV and AIDS

In 2003:

• Estimated adult population infection rate: 1.9 %
• Estimated number of PLHAs among adult population: 123,100 (women
• 57,500)
• AIDS patients: ~ 20,000
• No National Data of HIV infected Children
• ( Some Organizations estimated 9,000 HIV infected Children and 3,000 AIDS)

The objective is to determine ARV firstline drug toxicity in 30 month of treatment among HIV/AIDS patients in cohort ESTHER Calmette Hospital.

This is a presentation on Critical Issues in the Success of National ARV Treatment Programs in Asia. The presentation was made by Director Kevin Robert Frost of TREAT Asia.

Main objective  • Retrospective cohort analysis of patients who started ARV 24 + 2 months ago and followed without viral load monitoring  Secondary objectives  • Description of success/failure clinico-immunological criteria at 24 months and at 6, 12 and 18 months  • Identification of the reasons for virological failure at 24 months  • Description of resistance mutations to ARV observed at 24 months  • Analysis of the observance of the patients still on ARV at 24 months  • Evaluation of ARV side-effects during the 24 months of treatment  • Pharmacological analysis of ARV at 24 months

The objectives of this presentation are to raise AIDS awareness among MSM, increase safer sexual behaviors among MSM and their sexual partners and increase access to “MSM-friendly” services for STI, VCT and HIV care and treatment.

Slides on Integration of VCCT Services into Sexual Reproductive Health Clinics. Presented by Dr. Ping Chutema, Director of Clinical Services, RHAC.

This presentation presents the findings of a case study of drug toxicity on a woman diagnosed as HIV positive. It also outlines a suggested management plan moving forward.